David P. Meeker - Feb 1, 2023 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
President and CEO, Director
Signature
/s/ Hunter C. Smith, Attorney-in-Fact for David P. Meeker
Stock symbol
RYTM
Transactions as of
Feb 1, 2023
Transactions value $
$0
Form type
4
Date filed
2/3/2023, 03:08 PM
Previous filing
Jul 1, 2022
Next filing
Jun 30, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Award $0 +56.5K $0.00 56.5K Feb 1, 2023 Common Stock 56.5K Direct F1, F2
transaction RYTM Stock Option (Right to Buy) Award $0 +230K $0.00 230K Feb 1, 2023 Common Stock 230K $27.35 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date.
F3 The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.